Analytical Data
-
Gene name
HLA-DQA1
- Application
-
Alternative Names
DC-1 alpha chainDC-alphaHLA-DCAMHC class II DQA1
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P01909
-
Expression Region
24-213aa
-
Molecular Weight
25.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HLA-DQA1 is a key gene that encodes a protein part of the major histocompatibility complex (MHC) class II molecules, which play a crucial role in the immune response by presenting peptides derived from extracellular proteins to CD4+ T cells. Research on HLA-DQA1 is significant due to its involvement in various autoimmune diseases, transplant rejection, and susceptibility to infections. Variations in HLA-DQA1 alleles have been linked to conditions such as type 1 diabetes, multiple sclerosis, and rheumatoid arthritis, highlighting its role in immune regulation and disease pathogenesis. The recombinant protein study of HLA-DQA1 allows for a better understanding of its structural and functional properties, aiding in the development of therapeutic strategies including vaccine design and immunotherapy. Advances in recombinant DNA technology facilitate the production of large quantities of HLA-DQA1 proteins, which can be used in assays to explore T-cell interactions, epitope mapping, and antigen presentation mechanisms. By characterizing HLA-DQA1 through biophysical and biochemical methods, researchers aim to elucidate the nuances of immune responses and improve clinical outcomes for patients with related immunological disorders. This research not only contributes to the fundamental knowledge of the immune system but also offers potential pathways for innovative treatments and personalized medicine approaches.
